Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Berubicin - Reata Pharmaceuticals

Drug Profile

Berubicin - Reata Pharmaceuticals

Alternative Names: Berubicin (B); Berubicin hydrochloride; Reata 744; RTA 744; WP744

Latest Information Update: 26 Mar 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Reata Pharmaceuticals
  • Class Anthracyclines; Antineoplastics
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain cancer; Glioma; Neoplastic meningitis

Most Recent Events

  • 26 Mar 2018 CNS Pharmaceuticals plans a phase IIa trial for Glioblastoma
  • 01 Dec 2017 CNS Pharmaceuticals and Reata Pharmaceuticals agree to develop berubicin for Glioblastoma
  • 16 Apr 2008 Interim efficacy, adverse events and pharmacokinetics data from a Phase-I trial in Glioblastoma presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top